Drug-Induced Liver Injury in Paediatrics: A Short Review
DOI:
https://doi.org/10.12974/2311-8687.2022.10.1Keywords:
Acetaminophen, Acute liver failure, Children, Drug-induced liver damage, Hepatotoxicity, ValproateAbstract
Drug-induced liver injury (DILI) is an under-recognized cause of paediatric liver disease. Although DILI in children accounts for about 1% of all reported adverse drug reactions throughout all age groups and less than 10% of all clinical DILI cases, it is responsible for about 20% of acute liver failure (ALF) cases. A wide range of drugs, herbal products and nutritional supplements have been associated with the development of DILI through dose-dependent, idiosyncratic or indirect mechanism. Limited literature is available in pediatric population, making DILI a still challenging diagnosis. An accurate medical history is of pivotal importance and should investigate about drug consumption, clinical and laboratory findings, individual and family risk factors for drug-related side effects or comorbidities, the timing of the injury onset after the implicated agent has been started (latency). Clinical presentation of DILI varies from asymptomatic or very mild to serious and sometimes fatal conditions; laboratory tests may be helpful in ruling out other causes of liver injury but, with few exceptions, they are aspecific. Early suspicion and prompt withdrawal of the offending drug play a key role for a successful management of most cases.
Rarely a specific therapy is available, as for acetaminophen toxicity, treated with N-acetylcysteine, and sodium valproate toxicity, where carnitine may be beneficial. Although controlled trials are not available yet, corticosteroids and ursodeoxycholic acid can be considered if no improvement is proven after discontinuation of drug.
The present short review is not intended to deal with all aspects concerning DILI but to focus on epidemiology, pathogenesis, clinical features, practical management and current challenges in paediatric age.
References
Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf 2010; 33(6): 503-22. https://doi.org/10.2165/11535340-000000000-00000 DOI: https://doi.org/10.2165/11535340-000000000-00000
Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52(6): 2065-76. https://doi.org/10.1002/hep.23937 DOI: https://doi.org/10.1002/hep.23937
Squires RH Jr, Shneider BL, Bucuvalas J, Alonso E, Sokol RJ, Narkewicz MR, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006; 148(5): 652-58. https://doi.org/10.1016/j.jpeds.2005.12.051 DOI: https://doi.org/10.1016/j.jpeds.2005.12.051
Star K, Norén GN, Nordin K, Edwards IR. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase. Drug Saf 2011; 34(5): 415- 28. https://doi.org/10.2165/11587540-000000000-00000 DOI: https://doi.org/10.2165/11587540-000000000-00000
Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36(2): 451-5. https://doi.org/10.1053/jhep.2002.34857 DOI: https://doi.org/10.1053/jhep.2002.34857
Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144(7): 1419- 25. https://doi.org/10.1053/j.gastro.2013.02.006 DOI: https://doi.org/10.1053/j.gastro.2013.02.006
Amin MD, Harpavat S, Leung DH. Drug-induced liver injury in children. Curr Opin Pediatr 2015; 27(5): 625-33. https://doi.org/10.1097/MOP.0000000000000264 DOI: https://doi.org/10.1097/MOP.0000000000000264
Hoofnagle JH, Björnsson ES. Drug-induced liver injury - types and phenotypes. N Engl J Med 2019; 381(3): 264-73. https://doi.org/10.1056/NEJMra1816149 DOI: https://doi.org/10.1056/NEJMra1816149
Shi Q, Yang X, Greenhaw JJ, Salminen AT, Russotti GM, Salminen WF. Drug-induced liver injury in children: clinical observations, animal models, and regulatory status. Int J Toxicol 2017; 36(5): 365-79. https://doi.org/10.1177/1091581817721675 DOI: https://doi.org/10.1177/1091581817721675
Zhou L, Maviglia SM, Mahoney LM, Chang F, Orav EJ, Plasek J, et al. Supratherapeutic dosing of acetaminophen among hospitalized patients. Arch Intern Med 2012; 172(22): 1721-8. https://doi.org/10.1001/2013.jamainternmed.438 DOI: https://doi.org/10.1001/2013.jamainternmed.438
Carrascosa MF, Salcines-Caviedes JR, Lucena MI, Andrade RJ. Acute liver failure following atorvastatin dose escalation: is there a threshold dose for idiosyncratic hepatotoxicity? J Hepatol 2015; 62(3): 751-2. https://doi.org/10.1016/j.jhep.2014.11.019 DOI: https://doi.org/10.1016/j.jhep.2014.11.019
Licata A. Adverse drug reactions and organ damage: the liver. Eur J Intern Med 2016; 28: 9-16. https://doi.org/10.1016/j.ejim.2015.12.017 DOI: https://doi.org/10.1016/j.ejim.2015.12.017
Miller ED, Abu-Sbeih H, Styskel B, Nogueras Gonzalez GM, Blechacz B, Naing A, et al. Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors. Am J Gastroenterol 2020; 115(2): 251-61. https://doi.org/10.14309/ajg.0000000000000398 DOI: https://doi.org/10.14309/ajg.0000000000000398
Fernández-Murga ML, Petrov PD, Conde I, Castell JV, Goméz-Lechón MJ, Jover R. Advances in drug-induced cholestasis: clinical perspectives, potential mechanisms and in vitro systems. Food Chem Toxicol 2018; 120: 196-212. https://doi.org/10.1016/j.fct.2018.07.017 DOI: https://doi.org/10.1016/j.fct.2018.07.017
Zhu Y, Li YG, Wang JB, Liu SH, Wang LF, Zhao YL, et al. Causes, features, and outcomes of drug-induced liver injury in 69 children from China. Gut Liver 2015; 9(4): 525-33. https://doi.org/10.5009/gnl14184 DOI: https://doi.org/10.5009/gnl14184
Molleston JP, Fontana RJ, Lopez MJ, Kleiner DE, Gu J, Chalasani N; Drug-Induced Liver Injury Network. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr 2011; 53(2): 182-9. https://doi.org/10.1097/MPG.0b013e31821d6cfd DOI: https://doi.org/10.1097/MPG.0b013e31821d6cfd
Kumar A, Sood V, Khanna R, Verma SK, Mehra N, Rawat D, et al. Clinical spectrum and outcome of pediatric drug induced liver injury. Indian J Pediatr 2018; 85(8): 676-78. https://doi.org/10.1007/s12098-017-2570-3 DOI: https://doi.org/10.1007/s12098-017-2570-3
McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology 2010; 51(4): 1450-60. https://doi.org/10.1002/hep.23533 DOI: https://doi.org/10.1002/hep.23533
Björnsson HK, Björnsson ES. Drug-induced liver injury: pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med 2021: S0953- 6205(21)00375-7. https://doi.org/10.1016/j.ejim.2021.10.035 DOI: https://doi.org/10.1016/j.ejim.2021.10.035
Livertox: clinical and research information on drug-induced liver injury. https://www.ncbi.nlm.nih.gov/books/NBK548517 (accessed December, 2021).
Murray KF, Hadzic N, Wirth S, Bassett M, Kelly D. Drugrelated hepatotoxicity and acute liver failure. J Pediatr Gastroenterol Nutr 2008; 47(4): 395-405. https://doi.org/10.1097/MPG.0b013e3181709464 DOI: https://doi.org/10.1097/MPG.0b013e3181709464
Serranti D, Montagnani C, Indolfi G, Chiappini E, Galli L, de Martino M. Antibiotic induced liver injury: what about children? J Chemother 2013; 25(5): 255-72. https://doi.org/10.1179/1973947813Y.0000000090 DOI: https://doi.org/10.1179/1973947813Y.0000000090
Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354(7): 731-9. https://doi.org/10.1056/NEJMra052270 DOI: https://doi.org/10.1056/NEJMra052270
Davern TJ 2nd, James LP, Hinson JA, Polson J, Larson AM, Fontana RJ, et al. Measurement of serum acetaminophenprotein adducts in patients with acute liver failure. Gastroenterology 2006; 130(3): 687-94. https://doi.org/10.1053/j.gastro.2006.01.033 DOI: https://doi.org/10.1053/j.gastro.2006.01.033
Njoku DB, Greenberg RS, Bourdi M, Borkowf CB, Dake EM, Martin JL, et al. Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists. Anesth Analg 2002; 94(2): 243-9. https://doi.org/10.1213/00000539-200202000-00003 DOI: https://doi.org/10.1213/00000539-200202000-00003
Farrell GC, Liddle C. Drugs and the liver updated, 2002. Semin Liver Dis 2002; 22(2): 109-13. https://doi.org/10.1055/s-2002-30106 DOI: https://doi.org/10.1055/s-2002-30106
Lancaster EM, Hiatt JR, Zarrinpar A. Acetaminophen hepatotoxicity: an updated review. Arch Toxicol 2015; 89(2): 193-9. https://doi.org/10.1007/s00204-014-1432-2 DOI: https://doi.org/10.1007/s00204-014-1432-2
Chiew AL, Reith D, Pomerleau A, Wong A, Isoardi KZ, Soderstrom J, et al. Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand. Med J Aust 2020; 212(4): 175-83. https://doi.org/10.5694/mja2.50428 DOI: https://doi.org/10.5694/mja2.50428
Yarema MC, Johnson DW, Berlin RJ, Sivilotti ML, Nettel- Aguirre A, Brant RF, et al. Comparison of the 20-hour intravenous and 72-hour oral acetylcysteine protocols for the treatment of acute acetaminophen poisoning. Ann Emerg Med 2009; 54(4): 606-14. https://doi.org/10.1016/j.annemergmed.2009.05.010 DOI: https://doi.org/10.1016/j.annemergmed.2009.05.010
Guo HL, Jing X, Sun JY, Hu YH, Xu ZJ, Ni MM, et al. Valproic acid and the liver injury in patients with epilepsy: an update. Curr Pharm Des 2019; 25(3): 343-51. https://doi.org/10.2174/1381612825666190329145428 DOI: https://doi.org/10.2174/1381612825666190329145428
Stine JG, Lewis JH. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol 2016; 10(4): 517-36. https://doi.org/10.1586/17474124.2016.1127756 DOI: https://doi.org/10.1586/17474124.2016.1127756
Mahadevan SB, McKiernan PJ, Davies P, Kelly DA. Paracetamol induced hepatotoxicity. Arch Dis Child 2006; 91(7): 598-603. https://doi.org/10.1136/adc.2005.076836 DOI: https://doi.org/10.1136/adc.2005.076836
Lee WS, McKiernan P, Kelly DA. Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United kingdom. J Pediatr Gastroenterol Nutr 2005; 40(5): 575-81. https://doi.org/10.1097/01.MPG.0000158524.30294.E2 DOI: https://doi.org/10.1097/01.MPG.0000158524.30294.E2
